Clinical Trials Logo

Clinical Trial Summary

The purpose of the REVIPSY study is to measure retinal and the visual cortical electrophysiological responses in situations at risk of psychosis in patients who have experienced a first psychotic episode. A perspective of this project will be to create new electrophysiological biomarkers predictive of the risk of conversion to psychosis


Clinical Trial Description

The severity of psychotic disorders and their disabling potential in young patients represent a major public health problem. These populations are affected by high-level cognitive disorders associated with highly integrative functions. However, there is increasing evidence of lower-level impairments, including vision. Indeed, the literature reports electrophysiological abnormalities at the retinal level, reflected by an alteration of the signal transmission in the retinal ganglion cells (RGC), photoreceptors and bipolar cells. At the cortical level, numerous studies report electrophysiological abnormalities associated with the activity of the primary visual areas. These both electrophysiological measurements have the advantage of being objective, reliable and reproducible, thus leading to new research perspectives concerning the link between retinal and cortical measures in psychosis. These measures could also be interesting for the detection of the risk of conversion to psychosis, before it develops. The transition to a state of psychosis is in fact marked by the appearance of symptoms, which can occur several years before the diagnosis and impact the duration of the untreated psychosis. Thus, the notion of a clinical state at high risk of psychosis (CHRP) defines a population of patients said to be at risk of psychosis. These symptoms precede the occurrence of the first psychotic episode (FEP), indicating the clear transition to psychotic illness. The questions that arise at the present time concerned the early detection and intervention of psychosis during this prodromal phase. This detection could be done via electrophysiological measures associated to the visual processing, but also via measures of neuropsychological evaluations and behavioral measures. That is why, a study on retinal and visual cortical alterations coupled with neuropsychological assessments and behavioral measures in populations at risk of populations at risk of CHRP psychosis and in FEP would potentially reveal predictive biomarkers of the pathology. Such a project could lead to the development of retino-cortical biomarkers in mental health and will eventually lead to to create ultra-portable, reliable and routinely usable measurement devices for the early detection of psychosis in clinic. Main objective: To measure retinal and visual cortical electrophysiological responses in clinical subjects at high risk of psychosis (CHRP) in comparison with first-episode psychotic patients (FEP) and healthy controls (CS) Secondary objective(s) : Compare ERG traces obtained from the "Retinaute" portable ERG device produced by the company BioSerenity with ERG traces obtained from a standard device ERG measurement device "MyPackOne" produced by the company Metrovision among healthy controls To measure performance on neuropsychological tests in clinical subjects at high risk of psychosis (CHRP) compared to patients with a first episode of psychosis (FEP) Measuring temporal prediction in tactile modality (unimodal) with a motor task, in clinical subjects at high risk of psychosis (CHRP) in comparison with first-episode patients (FEP) and healthy controls (CS) Measuring temporal prediction in visual and tactile (multimodal) modalities/Measuring temporal prediction in visual modality (unimodal) with a classical perceptual task in clinical subjects at high risk of psychosis (CHRP) in comparison with patients with a first psychotic episode with a first episode of psychosis (FEP) and healthy controls (CS) To compare the sensitivity of behavioural and EEG measures to the prediction of tactile vs. visual stimuli, and multimodal vs. unimodal ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05167396
Study type Interventional
Source Centre Psychothérapique de Nancy
Contact Irving REMY
Phone 0383925267
Email irving.remy@bioserenity.com
Status Recruiting
Phase N/A
Start date January 26, 2022
Completion date January 26, 2026

See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Recruiting NCT01888783 - Two Measures of Tactile Acuity in CRPS Type I Patients N/A
Recruiting NCT03741478 - Intranasal Insulin and Olanzapine Study in Healthy Volunteers Phase 1
Completed NCT02919774 - Pomaglumetad Effects on Glutamate Biomarkers Phase 1
Completed NCT01460394 - Normative Data of Brain Network Activation in Adolescents and Young Adults
Completed NCT00771940 - Peripheral Metabolic Effects of Ghrelin Phase 1
Recruiting NCT06068322 - Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease N/A
Active, not recruiting NCT02652195 - Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II Phase 2
Recruiting NCT06270108 - The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia Early Phase 1
Withdrawn NCT04320966 - Neurovascular Complications and White Matter Damage in Acquired Anemias
Recruiting NCT05046184 - Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets Phase 2
Completed NCT03134963 - Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Completed NCT03081546 - Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease
Completed NCT04085094 - Gender Differences in Renal Functioning and Disease
Completed NCT03520543 - [11C]Yohimbine PET Study of alpha2-AR Phase 1
Recruiting NCT06098612 - PET Imaging Evaluation of [11C]SY08 Early Phase 1
Completed NCT02134951 - Biomarker Assessment of Glutamatergic Target Engagement Phase 4
Active, not recruiting NCT05056610 - Confocal Laser Endomicroscopy to Determine Influence of Food Antigens on Mucosal Integrity N/A
Recruiting NCT05656378 - A Repository to Study Host-Microbiome Interactions in Health and Disease